Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy
Issued Date
2024-01-01
Resource Type
ISSN
03022838
eISSN
18737560
Scopus ID
2-s2.0-85212640623
Journal Title
European Urology
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Urology (2024)
Suggested Citation
Koshkin V.S., Danchaivijitr P., Bae W.K., Semenov A., Ozyilkan O., Su Y.L., Arranz Arija J.A., Tsujihata M., Bögemann M., Hendriks M.P., Delgado S.N., Rosenbaum E., Lopez K.A., Bavle A., Liu C.C., Imai K., Furka A. Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy. European Urology (2024). doi:10.1016/j.eururo.2024.11.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102563
Title
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy
Author's Affiliation
NoordWest Ziekenhuisgroep
Siriraj Hospital
Instituto Nacional de Enfermedades Neoplasicas
Hospital General Universitario Gregorio Marañón
UCSF School of Medicine
Chang Gung Memorial Hospital
Başkent Üniversitesi
Rabin Medical Center Israel
Osaka Rosai Hospital
Merck & Co., Inc.
Universitätsklinikum Münster
Debreceni Egyetem
Chonnam National University Medical School and Hwasun Hospital
West German Cancer Center
Oncomédica
Ivanovo Regional Oncology Dispensary
Siriraj Hospital
Instituto Nacional de Enfermedades Neoplasicas
Hospital General Universitario Gregorio Marañón
UCSF School of Medicine
Chang Gung Memorial Hospital
Başkent Üniversitesi
Rabin Medical Center Israel
Osaka Rosai Hospital
Merck & Co., Inc.
Universitätsklinikum Münster
Debreceni Egyetem
Chonnam National University Medical School and Hwasun Hospital
West German Cancer Center
Oncomédica
Ivanovo Regional Oncology Dispensary
Corresponding Author(s)
Other Contributor(s)
Abstract
Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreatment. This post hoc analysis evaluated pembrolizumab retreatment in patients with advanced/metastatic urothelial carcinoma who received pembrolizumab in KEYNOTE-045, KEYNOTE-052, or KEYNOTE-361, and either stopped pembrolizumab after a complete response (CR) or completed pembrolizumab (35 cycles [∼2 yr]) with an objective response or stable disease. Upon disease progression, protocol-specified pembrolizumab retreatment (200 mg intravenously every 3 wk) was administered for ≤17 cycles. Forty-nine patients met the criteria and were included. The median follow-up was 24.4 mo (range, 1.4–53.5). The median time between first-course therapy cessation and pembrolizumab retreatment was 10.7 mo (1.0–36.3). Twenty patients (41%) had an objective response with pembrolizumab retreatment, 65% of whom had a CR to first-course treatment. The median retreatment duration was 8.3 mo (range, 0.0–13.2); the median duration of response was 14.0 mo (2.1+ to 20.5). From retreatment initiation, the median (95% confidence interval) progression-free survival and overall survival were 9.5 mo (5.6–15.0) and 25.7 mo (21.5–27.5), respectively. Treatment-related adverse events occurred in 45% (grade 3–4: 6%; grade 5: 0%). Data suggest that pembrolizumab retreatment is beneficial and tolerable for some patients with advanced/metastatic urothelial carcinoma who previously had a CR or completed 2 yr of pembrolizumab.